Soligenix Inc. (NasdaqCM: SNGX) has been sharing compelling updates highlighting the milestones reached during the past year. June was an especially busy month, with updates on its two pivotal phase 3 trials, news from its Public Health Solutions business segment, and its Chief Scientific Officer being featured in a podcast talking about the company’s COVID-19 vaccine candidate.
Also, the company’s shares are now included in the Russell Microcap® Index, a listing that remains in place for one year and means automatic inclusion in the appropriate growth and value style indexes. Soligenix announced it has completed patient enrollment in its Phase 3 DOM-INNATE (“Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity”) study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in head and neck cancer patients. Investors are also focused on the positive top-line data for its SGX301 trial, targeting cutaneous T-cell lymphoma. Trial data was released in March that showed a statistically significant benefit to patients treated in the study. Additional 12-week follow-on data showed continued patient improvement for the indication. That drug is looking to become a first-line treatment and potentially become an option for treatment against competing drugs from Ligand Pharmaceuticals (NASDAQ: LGND) and Sanofi (NYSE: SNY).
With these milestones leading to what could become a breakout year for the company, PCG Digital’s, Kerry Corbitt sat with Soligenix CEO Chris Schaber, Ph.D., to find out more about the opportunities ahead for Soligenix as the company enters the back half of 2020.
Video Link: https://www.youtube.com/embed/NUorKFFYAFw
Bottom Line For 2020
The above podcast points toward several potentially important milestones. The first may come from the completion and announcement of top-line results from its other pivotal Phase 3 study with SGX942 in the treatment of oral mucositis in patients with head and neck cancer. There is no FDA-approved drug for oral mucositis in patients undergoing treatment for solid tumors. Updates from its Public Health Solutions business segment and its other Phase 3 trial SGX301 are also expected.
With several programs in focus, the second half of the year may allow Soligenix to build on the positive momentum from the past two years. And according to the Soligenix CEO, the company may be in its best position ever to provide shareholder value by delivering on multiple potential catalysts across the company’s robust rare disease pipeline.
PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures